Communiqués Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 14/07/2026			Après clôture 02:00:00
476,31 ^USD	-0,82 %		475,80	-0,11 %

13/07	L'American Academy of Orthopaedic Surgeons lance un nouveau centre de ressources sur la gestion de la douleur en partenariat avec Curonix LLC, Pacira BioSciences, Inc., Vertex Pharmaceuticals et Viatris	CI
13/07	VERTEX PHARMACEUTICALS INCORPORATED : Opinion positive de UBS	ZM

Communiqués

07/07	Vertex to Announce Second Quarter 2026 Financial Results on August 3rd	BU
07/07	Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis	AQ
06/07	Vertex to Acquire Crinetics Pharmaceuticals	BU
02/07	Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	BU
11/06	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions	BU
05/06	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	BU
03/06	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	BU
01/06	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	BU
11/05	Vertex to Participate in Upcoming May Investor Conferences	BU
07/05	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	AQ
06/05	Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	BU
06/05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)	PU
04/05	Vertex Pharmaceuticals Incorporated : Q1 26 VRTX Earnings Presentation	PU
04/05	Vertex: Q1 Earnings Snapshot	AQ
04/05	Vertex Reports First Quarter 2026 Financial Results	BU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Corporate Responsibility Report	PU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Data Summary	PU
06/04	Vertex to Announce First Quarter 2026 Financial Results on May 4th	BU
01/04	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States	BU
25/03	Vertex Pharmaceuticals Incorporated : 2025 (2025 Political Engagement Principles)	PU
13/03	AM Best Affirms Credit Ratings of Torreyana Insurance Company, Inc	AQ
09/03	Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy	BU
05/03	Vertex to Participate in Upcoming March Investor Conferences	BU
05/03	Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures	BU
17/02	Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3	BU